Debra M Foster is currently affiliated with Spectral Medical Inc.
The majority of her career has been focused on clinical research in the area
of sepsis, specifically endotoxemic sepsis. Her achievements in this realm are
that she ran a multicenter, multinational clinical study for the EAA (endotoxin
activity assay), the results of which were submitted to the FDA and other
regulatory authorities for approval. To follow, she was the project lead of a
multicenter, North American study for an anti-endotoxin therapy, the
polymyxin-B hemoperfusion cartridge. This work led her to become Vice-President
of clinical development for Spectral Medical. Currently, she is overseeing a
second study for the polymyxin-B cartridge. The results of this study may
become a disruptor for clinical research in sepsis.
Debra M Foster is currently affiliated with Spectral Medical Inc.
The majority of her career has been focused on clinical research in the area
of sepsis, specifically endotoxemic sepsis. Her achievements in this realm are
that she ran a multicenter, multinational clinical study for the EAA (endotoxin
activity assay), the results of which were submitted to the FDA and other
regulatory authorities for approval. To follow, she was the project lead of a
multicenter, North American study for an anti-endotoxin therapy, the
polymyxin-B hemoperfusion cartridge. This work led her to become Vice-President
of clinical development for Spectral Medical. Currently, she is overseeing a
second study for the polymyxin-B cartridge. The results of this study may
become a disruptor for clinical research in sepsis.